Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.61 |
| ▸ | PRKDC | P78527 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14032316 | 0.89 | PRKDC (0.52) | ADRB1PRKDCAKR1C3MAPTRAB9A | |
| SCHEMBL29833111 | 0.88 | PRKDC (0.51) | ADRB1PRKDCAKR1C3MAPTRAB9A | |
| SCHEMBL5123031 | 0.88 | PRKDC (0.51) | ADRB1PRKDCAKR1C3MAPTRAB9A | |
| SCHEMBL9231063 | 0.88 | PRKDC (0.51) | ADRB1PRKDCAKR1C3MAPTRAB9A | |
| SCHEMBL27869400 | 0.88 | PRKDC (0.51) | ADRB1PRKDCAKR1C3MAPTRAB9A | |
| SCHEMBL2208450 | 0.86 | AKR1C3 (0.68) | ADRB1PRKDCAKR1C3MAPTRAB9A | |
| SCHEMBL19475147 | 0.84 | AKR1C3 (0.51) | ADRB1PRKDCAKR1C3MAPTRAB9A | |
| SCHEMBL4349056 | 0.84 | AKR1C3 (0.66) | ADRB1PRKDCAKR1C3MAPTRAB9A | |
| SCHEMBL3363814 | 0.84 | NQO2 (0.57) | MAPTRAB9AKDM4EKMT2AMEN1 | |
| SCHEMBL3359954 | 0.84 | NQO2 (0.57) | MAPTRAB9AKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562817-B1 | ORGANIC MATERIALS WITH SPECIAL OPTICAL EFFECTS | CENTRE NAT RECH SCIENT (FR) | 2023-11-15 | — | — | EP | disclosed |
| US-11613513-B2 | Organic materials with special optical effects | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2023-03-28 | — | — | US | disclosed |
| CN-112262128-A | Method for forming aryl carbon-nitrogen bond by illumination and photoreactor for carrying out the reaction | 科罗拉多州立大学研究基金会 | 2021-01-22 | — | — | CN | disclosed |
| US-20200147581-A1 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200147581-A1 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-05-14 | — | — | US | disclosed |
| US-20190345122-A1 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190345122-A1 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190337885-A1 | Organic Materials with Special Optical Effects | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-11-07 | — | — | US | disclosed |
| US-8404681-B2 | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404681-B2 | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404681-B2 | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | LUITPOLD PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | LUITPOLD PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | LUITPOLD PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | DCK, DTYMK, XPA | ADRB1 3632/4885PRKDC 12/4885AKR1C3 3345/4885 |
| US-20190337885-A1 | Organic Materials with Special Optical Effects | IK, TYR, MITF | ADRB1 3729/4885PRKDC 4402/4885AKR1C3 1797/4885 |
| US-11613513-B2 | Organic materials with special optical effects | IK, TYR, MITF | ADRB1 3729/4885PRKDC 4402/4885AKR1C3 1797/4885 |
| US-20190345122-A1 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | TYR, CRY2, CRY1 | ADRB1 2844/4885PRKDC 483/4885AKR1C3 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.